CONMED (CNMD)
(Delayed Data from NYSE)
$75.24 USD
-0.11 (-0.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $75.25 +0.01 (0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum A VGM
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 8 |
Average Target Price | $82.00 |
LT Growth Rate | 19.30% |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 139 of 253 |
Current Quarter EPS Est: | 0.99 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | Wells Fargo Securities | Vikramjeet S Chopra | Hold | Hold |
7/31/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/25/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
3/15/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.